Skip to main content

Opioid overdose antidote Narcan will be available over-the-counter by late summer after FDA approval

Emergent BioSolutions stock gains after FDA approves the company's opioid overdose-reversing nasal spray, Narcan, for over-the-counter sales.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.